Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database-Reference-Cited by-同舟云学术

Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database

Published:2016-11-30 Issue:2 Volume:1 Page:112-121
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Fallah Jaleh¹²^ORCID,Qunaj Lindor¹^ORCID,Olszewski Adam J.¹³^ORCID

Affiliation:

1. Alpert Medical School, Brown University, Providence, RI;

2. Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket, RI; and

3. Division of Hematology-Oncology, Rhode Island Hospital, Providence, RI

Abstract

Key Points The proportion of PCNSL patients receiving chemotherapy increased, but remains 31% lower in community than in academic cancer programs. Estimated overall survival in PCNSL is 37.7% at 3 years and reaches 51.8% in the subgroup treated with multiagent chemotherapy.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/2/112/877613/advances000927.pdf

Reference42 articles.

1. Diagnosis and treatment of primary CNS lymphoma;Korfel;Nat Rev Neurol,2013

2. How I treat primary CNS lymphoma;Ferreri;Blood,2011

3. The role of whole brain radiation in primary CNS lymphoma;Kasenda;Blood,2016

4. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315;Nelson;Int J Radiat Oncol Biol Phys,1992

5. Central nervous system cancers: clinical practice guidelines in oncology;Brem;J Natl Compr Canc Netw,2005

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study;Signal Transduction and Targeted Therapy;2024-09-04

2. Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma;Journal of Clinical Medicine;2024-08-13

3. Primary CNS Lymphoma: age as a prognostic biomarker;2024-03-27

4. Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis;Blood Advances;2023-09-15

5. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—Outcomes indicative for improved survival overtime;Hematological Oncology;2023-07-05